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ABSTRACT: Antimicrobial peptides (AMPs) are small molecules 
produced by virtually all living organisms as a part of the innate 
immune system. They present a broad spectrum antimicrobial activity 
against a myriad of microorganisms, but also anti-inflammatory, 
immunomodulatory and antitumor effects, among others. Therefore, 
it was our objective to compile and analyze the current information 
about natural and synthetic AMPs, regarding their general mechanisms 
of action, potentials, and limitations for clinical use, especially for 
the treatment of Staphylococcus aureus infections. Furthermore, 
we intended to briefly discuss new routes of administration and the 
emergence of bacterial resistance to AMPs. To do so, two databases, 
PubMed and Scopus, and the keywords “Staphylococcus aureus”, 
“antimicrobial peptide” and “novel antibiotics” were used, and the 
articles were filtered by the English language for the period between 
2011 and 2016. We found that AMPs possess different properties, 
with characteristic antimicrobial activities and secondary effects. 
Moreover, we also pointed some modifications that could be used to 
design new AMPs and different routes of administration that could 
be used to improve AMP capacity or to adapt it to a specific purpose, 
such as preventing biofilm formation in catheters or treating a specific 
disease. On the other hand, they also present limitations that include: 
development of bacterial resistance, cytotoxicity, and reduced stability, 
sometimes lower efficacy when compared to the actual treatment, high 
costs of production and also some inconsistent results between articles, 
which we believe that may be related to differences in methods and/or 
strains of S. aureus investigated. 
Keywords: Anti-bacterial agents/adminstration & dosage; Reference 
drugs; Staphylococcus aureus/drug effects; Staphylococcal infections/
prevention & control; Staphylococcus aureus/drug therapy.
RESUMO: Peptídeos antimicrobianos (AMPs) são pequenas moléculas 
conservadas evolutivamente e encontradas virtualmente em todos os 
organismos vivos como parte de sua imunidade inata. Eles possuem 
um amplo espectro de atividade antimicrobiana contra diversos 
microrganismos, mas também ação anti-inflamatória, imunomodulatória, 
antitumoral, dentre outros efeitos. Desse modo, nosso objetivo foi 
compilar e analisar as informações mais atuais sobre AMPs naturais 
e sintéticos, considerando seus mecanismos gerais de ação, bem 
como seu potencial e limitações para uso clínico, especialmente no 
tratamento de infecções por Staphylococcus aureus. Além disso, 
discutimos brevemente o uso de novas vias de administração e a 
possibilidade do desenvolvimento de resistência bacteriana aos AMPs. 
Para tanto, foram usadas duas bases de dados, PubMed e Scopus e os 
descritores “Staphylococcus aureus”, “peptídeos antimicrobianos” e 
“novos antibióticos”. Os artigos foram filtrados para a língua inglesa 
e foram selecionadas publicações entre 2011 e 2016. Os resultados 
foram em sua maioria compatíveis com o que se obteve em revisões 
prévias, a saber, que existe uma grande variedade de AMPs, cada qual 
com características, atividades antimicrobianas e efeitos secundários 
específicos. Ademais, também foram apontadas modificações que 
podem ser usadas para o planejamento de novos AMPs e diferentes vias 
de administração que podem ser usadas para aprimorar os potenciais 
de um AMP, ou adaptá-lo para um propósito específico, como a 
prevenção de formação de biofilmes em cateteres ou no tratamento 
de uma doença específica. Por outro lado, eles também possuem 
limitações, que incluem: desenvolvimento de resistência bacteriana, 
citotoxicidade e reduzida estabilidade, eventualmente baixa eficácia 
quando comparados ao tratamento atual, elevados custos de produção, 
e mesmo inconsistências de resultados entre artigos, o que acreditamos 
estar relacionado a diferenças no método e/ou a cepa de S. aureus usados.
Descritores: Antibacterianos/administração & dosage; Medicamentos 
de referência; Staphylococcus aureus/efeitos de drogas; Infecções 
estafilocócicas/prevenção & controle; Staphylococcus aureus/tratamento 
farmacológico.
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INTRODUCTION
Antimicrobial peptides (AMPs) are small, amphipathic and polycationic peptides, for the 
most part between 12 and 50 amino acids, that can exhibit 
linear structure, among which are included α-helical AMPs, 
or a circular structure, containing one or more disulfide 
bridges forming a β-sheet1. They are naturally produced, 
either constitutively or after a microbial stimulus2, and 
by a great variety of organisms, such as bacteria, fungi, 
plants, invertebrate animals, and mammals, including 
humans - in whom form an important line of defense 
of the innate immune response. AMPs commonly act 
through nonspecific mechanisms3. Because of this, it has 
been extensively discussed by the scientific community 
whether or not their widespread therapeutic application 
can induce resistance, and if the use of AMPs could lead 
to the same problems as those we face nowadays related 
to the indiscriminate use of antibiotics.
However, due to their capability to disrupt bacteria 
structure, recognize antigens and modulate innate immune 
response1, AMPs may be considered a potential novel 
alternative for the treatment of infections, such as those 
caused by antibiotic-resistant bacteria. Among them, 
Staphylococcus aureus infections deserve special attention, 
since they are frequent in the community and hospital 
settings, induce biofilm formation in medical devices4,5 
and include highly virulent and resistant strains, such as 
methicillin-resistant S. aureus (MRSA) and vancomycin-
resistant S. aureus (VRSA)4,5, which are related to 
complications and worse prognostic in intensive care unit 
patients.
However, scientists still face several questions 
and challenges related to the clinical use of AMPs for the 
treatment of severe infections6, such as their toxicity and 
non-specificity, effectiveness, stability, ways of application, 
selectivity, microorganism resistance, cross-resistance 
to human AMPs, proteolytic degradation7, peptide self-
aggregation8, high production costs, among others. 
Possible solutions include the synthetic/modified AMPs, 
molecules with the same basic characteristics of natural 
AMPs, but with certain synthetic modifications to reduce 
their toxicity, Minimum Inhibitory Concentration (MIC) 
and sensitiveness to protease activity, while maintaining 
(or increasing) its antibiotic potential9.
Thus, the present review aims to discuss the 
potentials and limitations of natural and synthetic AMPs 
for the treatment of S. aureus infections, focusing in the 
peptides produced in mammals or derived from them.
METHODS
In purpose to analyze the above theme, two 
databases were used: PubMed and Scopus, both accessed 
in October 2016.
Inclusion and exclusion criteria
We considered articles in the English language 
published between 2011 and 2016.
Review articles, those not available on open access 
or through University of São Paulo’s subscripts, those that 
primarily investigated a new methodology, other diseases, 
or immune, genetics and biochemistry mechanisms 
associated with AMPs were excluded.
Selection strategy
In PubMed, the search using the keywords 
“Staphylococcus aureus”, “antimicrobial peptide” and 
“novel antibiotics”, all together and without quotation 
marks, achieved 228 articles. In Scopus, the keywords 
“Staphylococcus aureus”, “antimicrobial peptide” and 
“antibiotics”, were used with quotation marks, resulting 
in 346 articles.
Primarily, the selected articles had their title 
evaluated based on the exclusion criteria. With this step, 
we reached 178 articles from PubMed and 346 articles 
from Scopus. They were unified and the repeated articles 
were excluded. Afterward, we got 377 articles, which had 
the abstract analyzed by the exclusion criteria, resulting 
in 177 articles.
Subsequently, these articles were classified by the 
origin of the AMP. As some articles approach more than 
one peptide, these were counted in more than one group, so 
that we had: Bacteria (22 articles), Protists (1 article), Fungi 
(5 articles), Plants (6 articles), Synthetics (36 articles), 
Invertebrates (34 articles), Fishes (8 articles), Amphibians 
(34 articles), Reptiles (5 articles), Birds (2 articles) and 
Mammals (34 articles). Aiming to detail a specific theme, 
the Mammals (34 articles) and Synthetic Mammals (12 
articles) articles were chosen for the review, given that they 
are one of the most studied, and the evolutionary similarity 
of some of them with human AMPs could eventually reduce 
adverse effects. Besides the selected articles, we added five 
reviews, two of them of 2017, to improve our knowledge 
about AMPs general mechanisms of action and resistance.
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RESULTS/DISCUSSION
The articles comprised, in general, information about 
how peptides act, bacterial resistance to them, favorable and 
unfavorable results for both natural and synthetic AMPs, 
and the possibilities for AMP administration. Thus, we 
divided the review into the 7 topics below, gathering MIC 
information in two tables, and toxicity information in two 
other tables.
Mechanisms of action
Due to their cationic characteristics, AMPs can 
steadily bind to negative charge components of the 
bacterial membrane, such as anionic phospholipids and 
lipoteichoic acids, which explains, in part, their preferential 
binding to bacterial membrane than eukaryotic zwitterionic 
amphipathic cell membrane10.
After binding to the bacterial membrane, AMPs act 
through either one of two different general mechanisms: 
I) disruption of the plasmatic membrane, causing cell 
permeabilization and leakage (membrane–targeting 
AMPs), and II) targeting specific intracellular components 
(intracellular–targeting AMPs)11. The majority of AMPs 
works by the first mechanism, which can occur either by 
forming pores (toroidal pore model), destabilizing the lipid 
bilayer (barrel-stave model) or by thinning the membrane 
(carpet model)3, ultimately promoting bacterial cell 
lysis. Regarding the second mechanism, AMPs can cross 
bacterial membrane without inducing permeabilization, 
by direct penetration or endocytosis, and interact with 
essential negative charged molecules, such as DNA, 
RNA, and proteins, interfering or inhibiting them3. Both 
mechanisms are non-specific, once it does not involve 
specific receptors, and attack essential parts of the bacterial 
cell. For that, AMPs resistance was believed to be rare1 – but 
now it is known that it is not impossible, and it has been 
increasingly detected. Indeed, bacteria exposed to sublethal 
doses of AMPs in vitro showed resistance, and sometimes, 
antibiotics cross-resistance10.
Besides their direct antimicrobial activity, AMPs 
may also possess immune modulatory activities12.
Bacterial resistance to AMPs
Considering the wide and unspecific mechanisms 
of action of AMPs, as well as the secular existence of 
 Figure 1. Methods - Selection flowchart for the articles
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these molecules, it is not unexpected that pathogens 
developed mechanisms “to dodge” this immune defense 
pathway. These resistance mechanisms follow three 
major approaches: I) inhibition of AMPs binding or entry 
into the bacterial cell, II) removal of AMPs that got into 
the pathogen cell, and III) modulation of host’s AMPs 
production. For S. aureus, the first and last strategies are 
the most frequent.
Concerning the inhibitory effects, S. aureus is 
capable of changing its surface charge, so it becomes less 
negative, thus limiting AMPs interaction. For example, it 
modifies its teichoic acid through D-alanylation encoded 
by the dltABCD operon, or through aminoacylation 
with L-alanine or L-lysine encoded by the mprF gene. 
Curiously, several host AMPs can paradoxically favor 
these modifications, restricting their own antimicrobial 
function. LL-16, for example, can naturally induce Dap, 
which is an operon of lysine biosynthesis enhancing, thus, 
this amino acid production. Analogously, brilacidin induces 
GraSR, a MprF member, even in doses as lower as MIC and 
quickly than LL-1613. The importance of these pathways is 
still reaffirmed once S. aureus null mutants of either dlt or 
mprf genes become more susceptible to mammalian AMPs, 
especially to defensins14.
Besides the teichoic acid, S. aureus also protects 
its surface by other molecules. The incorporation of long-
chain unsaturated fatty acids in the bacterial membrane, for 
example, increases S. aureus resistance for platelet-derived 
AMPs. In the same way, staphylokinase either inactivates 
some AMPs, such as mCRAMP and alpha-defensins, or 
enhances tissue invasion14. 
The production of other extracellular molecules by 
S. aureus is also known to limit AMP action15. For instance, 
the V8 protease is capable to degrade LL-375 and several 
other S. aureus’ molecules are capable of inhibiting LL-37 
and different AMPs by forming molecular complexes with 
low stability16.
Finally, S. aureus has an efflux system that actively 
removes AMPs that enter the cell. One of the major pumps 
is QaCA, a protein encoded by the commonly found pSK1 
plasmid, which already induced platelet AMP resistance 
in rabbits and possibly promotes changes in membrane 
fluidity14. Brilacidin and LL-16 act in similar pathways, 
encoding genes that enhance ABC transporters, which are 
responsible for the active efflux of AMPs13.
Therapeutic potential and limitations to the treatment 
of S. aureus infection
AMPs can be natural or synthetic – and not 
necessarily synthetic compounds are better than the natural 
ones3,9. Some also present secondary effects that may 
improve their clinical use, such as inhibition of biofilm 
formation and/or biofilm disruption. This is of great 
importance in clinical scenarios, as biofilm formation in 
medical devices (catheters, implants)5,17,18 and skin wounds 
have major implications.
AMPs also have some limitations, varying among 
them, which are related mostly to cytotoxicity/low 
selectivity3,19, low stability19,20, and others, both for natural 
and synthetic AMPs.
Potentials of natural AMPs
Although both bacterial evasion and general 
limitations of AMPs may impair some of their actions, 
several peptides are bacteriostatic or bactericidal (Table 
1) and play other beneficial roles, such as reduction of 
inflammatory effects, participation in wound healing, 
immune modulation and even antitumoral activity. 
Concerning bacteriostatic activity, some AMPs, 
such as HNP-1 and HNP-2, can only control pathogen 
growth by inhibiting exotoxins production, without altering 
CFUs24, while others, such as BMAP-28 and LL-37, can 
inhibit biofilm formation and also kill bacteria. Particularly, 
LL-37 achieves significant results, reducing S. aureus in 
nanomolar concentration7, ameliorating pneumonia in 
rats and destroying biofilms4. Nonetheless, despite these 
potentials, some researches33 already demonstrated better 
results in S. aureus elimination using modified AMPs 
than using natural ones. This occurs, for example, when 
NFL20 achieve, in comparison to LL-37, the double rate 
of survival of human-cell lines in an in vitro toxicity test, 
and a higher bacterial killing in a plasma assay33, showing 
that novel AMPs could be more efficient than those that 
are traditionally studied, deserving researchers’ attention.
These factors and comparisons of new therapeutic 
possibilities are even more important when the AMPs’ 
response is analyzed for bacteria resistant to some 
traditional antibiotics, once it would be desired that these 
novel molecules be either better or as efficacious as 
them. This indeed occurred in some experiments, such as 
when Kowalski et al.30 demonstrated that brilacidin has 
antimicrobial activity against vancomycin-resistant S. 
aureus infection in rabbits’ damaged-cornea, and when Tai 
et al.25 showed the capability of specific alpha- (Crp-4 and 
RMAD-4) and theta-defensin (RTD-I) to reduce MRSA 
in vitro.
On the other hand, ambiguous and negative results 
were also found. In experiments testing BMAP-27, BMAP-
28 and P19(9/B), these peptides not only got higher MIC 
values for S. aureus than tobramycin (the antibiotic of 
choice used for chronic suppressive therapy in Cystic 
Fibrosis patients) but also lower bactericidal activity in 
a “Cystic Fibrosis-like” in vitro experiment - acidic pH 
(6.8), reduced O2 tension (5% CO2), and a chemically 
defined “synthetic CF sputum medium” mimicking the 
nutritional composition of CF sputum28. In another study, 
the peptide catestatin reached a maximum of 40% of the 
efficiency of tetracycline and cefotaxime in controlling S. 
aureus growth in vitro17, showing that it could not replace 
the current antibiotic therapy.
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Table 1. Natural AMPs MICs with corresponding strain and references
Peptide Strain MIC Author Peptide Strain MIC Author
AP-57 ATCC 25923 - Yang et al.21 HBD-3
Clinical 
isolates -
Köten et al.22
MRSA N315 Li et al.23
Bac2A ATCC 29213 >256 μg/mL 
(>180.18 μM)
Ebbensgaard et 
al.20 HNP-1
Clinical 
isolates
5.6 μg/mL 
(1.62 μM)
Merriman et al.24
Bac2a-NH2 ATCC 29213 128 μg/mL (90.1 μM)
Ebbensgaard et 
al.20 HNP-2
Clinical 
isolates
5.6 μg/mL
(1.62 μM) Merriman et al.
24
Bac7(1-35) Clinical isolates >32 μg/mL 
(>7.6 μM)
Pompilio et al.16 HNP-3 Clinical isolates - Tai et al.
25
BMAP27
KCTC1621 
(MSSA) 4 μM Lee et al.
3
Indolicidin
ATCC 25923 8 μg/mL 
(4.2μM)
Xu et al.26
Clinical isolates 9.7 μM Pompilio et al.16
ATCC 29213 32 μg/mL
(16.8 μM)
Ebbensgaard 
et al.20 
ATCC 25923 31.25 μg/mL
(16.4 μM)
Jindal et al.27
MRSA
Clinical isolates >19.5 μM Pompilio et al.28 Clinical isolates
>32 μg/mL
(>16.8 μM)
Pompilio et al.16
BMAP-28
Clinical isolates 4-32 μg/mL 
(1.3-10.4 μM)
Pompilio et al.28
Lactoferricin B 
(LfcinB)
ATCC 25923 64 μg/mL(20.5 μM) Feng et al.
29
Clinical isolates 16–32 μg/mL 
(5.2–10.4 μM)
Pompilio et al.16
ATCC 25923
- Noore et al.7
Clinical isolate
Brilacidin
Ciprofloxacin-
susceptible S. 
aureus
0.25 μg/mL
Kowalski et al.30 Lysozyme Clinical isolates - Köten et al.
22
Ciprofloxacin-
resistant S. aureus
MIC50 = 0.25 μg/mL and 
MIC90 = 0.5 μg/mL
Cap11 ATCC 29213 16–32 μg/mL 
(1.45-2.9 μM)
Ebbensgaard et 
al.20 LL37
ATCC 25923 
3 μM Noore et al.7Clinical 
isolates
MRSA 5 μM Banaschewski et al.31
Xen 29 
(pleural 
fluid isolate 
NCTC 8532 - 
MSSA)
28 μg/mL
(6.2 μM) Leszczyńska et 
al.32
ATCC 29213 14 μg/mL
(3.1 μM)
Clinical 
isolates >7 μM Pompilio et al.
16
ATCC 29213 40 μM Papareddy et al.33
Clinical 
isolates >50 μM Mishra et al.
5
ATCC 29213 
(MRSA) - Hou et al.
4
- - Song et al.19
Cap18 ATCC 29213 ≥32 μg/mL
 (≥7.2 μM)
Ebbensgaard et 
al.20 MBD-3
Clinical 
isolates
MBD-3: 
≤ 25μg/mL
Jiang et al.34
ATCC 25923
MBD-3 + 
Ampicilin: 
6,25μg/mL
Catestatin ATCC 25923 - Özçelik et al.17 NK-lysin ATCC 25923 - Chen et al.35
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Cathelicidin-
AM ATCC 2592
6.5 μg/mL
(1.5 μM) Yan et al.
36 P3 ATCC 29213
25 μg/mL 
(standard 
strain)
Zhang et al.9
12.5 μg/mL 
(resistant 
strain)
CATH-1
MRSA
- Banaschewski et al.31 Protegrin ATCC 25923
2-16µg/mL
(1-7.4 μM)
Barańska-Rybak 
et al.2WKZ-2
CATH-2
MRSA
- Banaschewski et al.31 Rattusin
ATCC 25923
4-8 μg/mL Patil et al.37
MRSA WKZ-2
ATCC BAA-
39
ATCC 43300
Cecropin P1 ATCC 29213 >256 μg/mL(>76.7 μM)
Ebbensgaard et 
al.20 RMAD4
Clinical 
isolates 1.5-3 μM Tai et al.
25
CRAMP MRSA WKZ-2 - Banaschewski et al.31 RNase7
Clinical 
isolates - Köten et al.
22
Cryptdin-4 
(Crp-4)
Clinical isolates 1.5-3 μM Tai et al.25 RTD-1 (teta defensin)
Clinical 
isolates 1.5 μM Tai et al.
25
eCATH1 ATCC 29213 >32 μg/mL Schlusselhuber et al.38 SMAP-29
Clinical 
isolates
4-8 μg/mL
(1.2-2.5 μM)
Pompilio et al.16
hLF1-11 ATCC 33591 64 μg/mL
(46.56 μM)
Costa et al.8 TSLP ATCC 29213 - Sonesson et al.15
Source: The authors.
Table 1. Natural AMPs MICs with corresponding strain and references     Continuation
Peptide Strain MIC Author Peptide Strain MIC Author
Even though the results are not always positive, 
AMPs secondary effects should be considered, as they 
may act synergistically with traditional treatments. Several 
natural AMPs can modulate host defense, reducing 
inflammatory cytokines4,25,33 or, in other cases, increasing 
anti-inflammatory ones33, what may support a favorable 
immunity polarization. Beneficial results of these roles 
were already noticed when RDT-1 reduced sepsis and 
peritonitis mortality in mice25, or when NFL20 inhibited 
LPS-induced NO responses and improved survival in mice 
with endotoxin-induced shock33.
Beyond the S. aureus direct control, it is interesting 
to point that AMPs, such as lactoferricin B, NK-18 and LL-
3739, exhibited activity against cancer cells. LL-37 stand out 
by also modulating inflammatory response, enhancing re-
epithelialization and wound healing19,32, characteristics that 
potentially improve host’s recovery and skin protection, 
given that S. aureus infection commonly occurs across the 
epithelial barrier.
Limitations of natural AMPs
These peptides commonly have dual characteristics 
that make them both antimicrobial and cytotoxic (Table 
2). The transition between these two activities occurs in 
a narrow difference of concentration, so it is difficult to 
establish a proper dose that could be therapeutic and the 
least harmful for an individual. For BMAP-27, for example, 
MIC is 4 μM, while hemolysis and macrophage toxicity 
occur, respectively, at 6.2 μM and 20 μM3. Furthermore, 
even in cases where high concentrations does not injure 
host’s cells, it could still impair AMPs’ antimicrobial 
potential, as was shown for LL-37, which in lower doses 
controlled S. aureus, but was ineffective in higher ones4. 
The obstacle is even greater when pharmacokinetic 
parameters, such as absorption, excretion, and half-life, 
are considered.
In addition, results described in some studies are 
not always reliable to predict and enhance AMP potential. 
Comparing peptides that belong to the same family, such 
as the cathelicidins group38 and the NK-lysins group35, 
it is possible to notice that some of the variants reached 
effectiveness against S. aureus, but others did not. Also, 
the same peptide could sometimes control just specific 
pathogens, being very effective for some but not for others. 
This occurs with TSLP, a molecule that significantly acts 
against to Gram negative, but not Gram positive bacteria15. 
Finally, assays conditions, especially salt concentration, 
are capable of changing AMPs results. Alpha defensins25, 
HD-5, and Crp-437, although reached S. aureus control in 
a given in vitro environment, had restricted activity when 
tested in physiological NaCl concentration.
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Table 2. Natural AMPs cytotoxicity and stability, with the corresponding reference
Peptide Toxicity Author Peptide Toxicity Author
Bac2A No hemolytic activity at 256 μg/mL
Ebbensgaard et 
al.20 HBD-3
LD90: 
0.39-0.78 μg/mL
Köten et al.22
Bac2a-NH2 No hemolytic activity at 256 μg/mL
Ebbensgaard et 
al.20 Indolicidin
12% hemolytic activity 
at 128 μg/mL Ebbensgaard et al.
20
BMAP27
Toxic for RAW264.7 cells only 
at >4 MIC Pompilio et al.16 Lactoferricin B (LfcinB)
0.86% hemolysis at 
MIC Feng et al.
29
<10% hemolysis at MIC
Brilacidin
Minimum irritant cornea 
concentration of 0,5% (more 
irritating than Vancomycin 5% 
for treating corneal infection but 
not to treat corneal ulcer)
Kowalski et al.30 LL37
10% HaCaT cell 
survival at MIC Papareddy et al.
33
No significant bacteria reduction 
in healthy cornea epithelium, 
but reaches better bactericidal 
results in damage epithelium 
(3.6-log reduction in CFU) when 
compared to Vancomycin 5% and 
saline intervention
Toxic and no protective 
effect in pneumonia up 
to 2 mg/kg
Hou et al.4
Cap11 Hemolytic activity 4% at 64 μg/mL
Ebbensgaard et 
al.20
P3
5% hemolysis at MI
Tai et al.25Cap18
Hemolytic activity 1% at 64 μg/
mL
Ebbensgaard et 
al.20
>95% HaCaT cell 
survival at MIC
Cathelicidin-
AM
1.7% hemolysis at 200μg/mL (31 
MIC) Yan et al.
36 LD50 = 160 mg/kg in 
mice
CATH-2
Causes elevation of IL-6, 
mild pulmonary edema, and 
inflammation Banaschewski 
et al.31 Rattusin
No cytotoxicity against 
human Caco-2 cells and 
no hemolysis at 100 μM 
(12.5-25 MIC)
Patil et al.37
CATH2 + BLES showed no 
adverse effect
Cecropin P1 No hemolytic activity at 256 μg/mL
Ebbensgaard et 
al.20 RMAD4
Non-cytotoxic and 
nonhemolytic until 100 
µg/mL (33-66 MIC)
Tai et al.25
Cryptdin-4 
(Crp-4)
Non-cytotoxic and non-hemolytic 
until 100 µg/mL (33-66 MIC) Tai et al.
25 RTD-1 (teta 
defensin)
Non-cytotoxic, non-
hemolytic at MIC Tai et al.
25
Source: The authors.
Potentials of synthetic AMPs
Synthetic peptides are a possible solution to 
overcome AMPs “flaws”, such as cytotoxicity, low stability, 
and low specificity, while maintaining (or even enhancing) 
their antimicrobial (Table 3) and/or antibiofilm potential1. 
Hybridization of active parts of two natural peptides with 
different properties is a possible method to achieve this 
objective29; amino acid substitution or deletion are also 
possibilities already being tested27.
Relations between molecular characteristics and 
AMP effectiveness are already being studied, so there are 
parameters that can be used as basis to the modifications 
one uses in the design of new AMPs. Hydrophobicity and 
cationicity are examples that are related to membrane 
interaction; however, increasing hydrophobicity is related 
to mammalian cell toxicity27 due to loss of specificity, while 
reducing it causes the opposite effect20. This was shown by 
the removal of the N-terminal hydrophobic amino acids 
from LL-37, which decreases its cytotoxicity without 
diminishing its antimicrobial effect7. Regarding positive 
charged amino acids of AMPs, Noore et al.7 reported, based 
on a study over LL-37, that the substitution of lysines for 
arginines decreased antistaphylococcal activity, showing 
that it is not only the positive charge number that is related 
to the AMP activity.
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Likewise, this influence of single amino acids on 
the overall effect of AMPs is also shown by the increase 
in antimicrobial activity caused by tryptophan addition; 
it is believed that tryptophan plays a role of anchor in 
membrane proteins and also helps the translocations of 
the AMP across the phospholipid bilayer40. Chain length 
and cyclization of the molecule, as well as amino acids 
substitution or position shifting, may also be related to 
reduced cytotoxicity and increased/maintained activity27, 
but require more investigation.
Table 3. Synthetic AMPs MICs with corresponding strain and reference
Peptide Strain MIC Author Peptide Strain MIC Author
17BIPHE2 Clinical isolates 1.56–3.1 μM Mishra et al.
5 LNK-16 ATCC 25923 6 μg/mL (2.6 μM) Xu et al.
26
BMAP-18 
analogs
KCTC 1621 
(MRSA) 4 μM Lee et al.
3 MKK34 ATCC 29213 -
Sonesson et 
al.15
BMAP-28 
analogs
Clinical 
isolates
3.1 μg/mL (A837) 
2.8 μg/mL (A838) 
2.4 μg/mL (A839) 
3.2 μg/mL (A840) Takagi et al.
41 NK-18 CMCC 26003 6.25 μg/mL Yan et al.
39
MRSA >5 μg/mL
Cap11 
derivative 
(Cap11-1-
18m2)
ATCC 29213 16 μg/mL(6.85 μM)
Ebbensgaard 
et al.20 NLF20
ATCC 
29213 10-20 μM
Papareddy et 
al.33
Cys-KR12 ATCC 25923 4–8 μg/mL (2.6–5.1 μM) Song et al.
19 P19(9/B) Clinical isolates
MIC50 = 8 μg/mL and 
MIC90 = 32 μg/mL
Pompilio et 
al.28
GF-17 Clinial isolates 1.56–3.1 μM Mishra et al.
5 P60.4Ac
LUH 
14616 
(MRSA)
- Göblyös et al.12
Indolicidin 
analogs ATCC 25923
IN1, IN2: 
31.25 μg/mL 
(15.5–17.25 μM) (S. 
aureus and MRSA)
Jindal et al.27 Psoriasin Clinical isolates - Köten et al.
22
IN3: 31.25 μg/mL 
(15.7 μM) 
(S. aureus) and 62.5 
μg/mL 
(31.4 μM) (MRSA)
IN4: 125 μg/mL 
(65.2 μM) (S. 
aureus) and 
250 μg/mL 
(130.4 μM) 
(MRSA)
JH-3 (P3 
analog) ATCC 29213
6.25 µg/mL 
(3.1 µM) (standard 
strain) and 3.125 
µg/mL (1.6 µM) 
(resistant strain)
Zhang et al.9
RN7-IN 
(Indolicidin 
based)
ATCC 
25923
MRSA
RN7-IN7: 
31.25 µg/mL (17.36 
µM)
Jindal et al.27RN7-IN6 = RNA7-IN8 
= RNA7-IN10: 7,81µg/
mL
(4,55µM)
LF15CA8 ATCC 25923 32 μg/mL (7 μM) Feng et al.29
Sub5-NH2 
(synthetic 
variant of 
Bac2A-
NH2)
ATCC 
29213
8 μg/mL
(4.64 μM)
Ebbensgaard 
et al.20
LFM23 ATCC 25923 32 μg/mL(11 μM) Zhao et al.
40 Tet213 Clinical isolates - Zhao et al.
18
LL-16 Newman 12.5 μg/mL(6.11 μM) Mensa et al.
13 - - - -
Source: The authors.
67
Baron GB, et al. Mammals’ antimicrobial peptides: potential and limitations for the treatment of Staphylococcus.
Another important example is the stability change 
that synthetic peptides may achieve. 17BIPHE2, an LL-
37 fragment, shows increased resistance to proteolytic 
degradation, including by S. aureus protease V85, which 
degrades LL-37. On the other hand, the same authors 
showed that P60.4Ac, another LL-37 derived peptide, had 
considerable V8 susceptibility, what points that not all 
modifications lead to peptide improvement.
Besides their antimicrobial effects, interesting 
results were found, for example, for Cys-KR1219. It acts in 
keratinocytes and fibroblast proliferation and keratinocytes 
differentiation, improving cell-cell attachment. Regarding 
its immunomodulatory response, Song et al.19 made 
a monocyte culture on a Cys-KR12-immobilized SF 
nanofiber membrane, and showed that this peptide 
interfered in monocytes TNF-α gene expression after LPS 
stimulation – and this interference may occur with other 
inflammatory stimuli as well. NLF20 and, to a higher 
extent, KYE28 (a longer peptide containing NLF20 
sequence and eight amino acids more) also showed some 
anti-inflammatory effects33. This is of great value for the 
treatment of S. aureus skin infection, considering this is a 
cutaneous pathogen that is responsible for a considerable 
number of bacterial skin infection in humans2.
More studies that analyze how molecular changes 
may affect AMPs parameters, such as protease susceptibility, 
antimicrobial effect and cytotoxicity are needed, so that 
AMP design becomes as rationalized and effective as 
possible. Nonetheless the wide diversity of AMPs and a 
non-correspondence that sometimes exists between activity 
and structure are still limitations to face.
 
Limitations of synthetic AMPs
Not all modifications generate a more effective 
peptide, or one with reduced cytotoxicity and higher 
stability (Table 4). For instance, BMAP-18 analogs3 showed 
the same or worst results in relation to their MIC and 
cytotoxicity than BMAP-18 and θ-defensins, as reduced 
disulfide bonds almost abolished bactericidal activity37, 
possibly due to increased susceptibility to proteolysis – in 
opposition to α- and β-defensins, which does not have 
their activity impaired by altering their redox status. Also, 
AMP activity is fragment-dependent15, as even relatively 
small modifications can provoke considerable changes in 
peptides activity. NLF20 and KYE28, for example, are 
very similar peptides (as discussed above, the second one 
contains NLF20 sequence and eight amino acids more), but 
NLF20 shows a stronger antimicrobial and anti-endotoxic 
effect, while KYE28 main effect is anti-inflammatory33.
Table 4. Synthetic AMPs cytotoxicity and stability, with the corresponding reference
Peptide Toxicity Author Peptide Toxicity Author
17BIPHE2 Non-cytotoxic, non- hemolytic at MIC Mishra et al.
5 JH-3
(P3 analog)
<5% hemolysis at MIC
Zhang et al.9>95% HaCaT cell survival 
at MIC
LD50 =180 mg/kg in mice
BMAP-18 
analogs
Non-cytotoxic for RAW264.7 
cells at MIC
Lee et al.3 LF15CA8 0.54% hemolysis at MIC Feng et al.29BMAP-18-W: 10% hemolysis at 
9.5 MIC; 
others at >64 MIC
Cap11 
derivative 
(Cap11-1-
18m2)
52 ± 6% hemolytic activity at 
64 μg/mL (4 MIC)
Ebbensgaard 
et al.20 LFM23
0.813 ± 0.012% hemolysis 
at MIC Zhao et al.
40
Cys-KR12
No citotoxicity against HaCaT 
cells or NHDF at ≥100 μg/mL 
(12.5-25 MIC)
Song et al.19 NLF20 60-70% HaCaT cell survival at MIC Papareddy et al.
33
GF-17 Non-cytotoxic, non- hemolytic at MIC Mishra et al.
5 RN7-IN 
(Indolicidin based) <5% hemolysis at MIC Jindal et al.
27
Indolicidin 
analogs <5% hemolysis at MIC Jindal et al.
27
Sub5-NH2 
(synthetic variant of 
Bac2A-NH2)
No hemolytic activity at 256 
μg/mL (32 MIC) Ebbensgaard et al.
20
Source: The authors.
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These differences can be somewhat explained 
by the relatively restricted knowledge of the correlation 
between molecular characteristics of AMPs and their 
effect on bacterial membrane. One feature that probably is 
related to this limitation is that the majority of the studies 
on the interaction of cationic peptides with membranes 
have been developed using a liposome model39 and not 
bacterial membranes. Nonetheless, even with suitable study 
models, discrepant results in vitro and in vivo may occur; 
for instance, JH-3 showed the highest hemolytic effect in 
vitro, but the lowest value in vivo, when compared to the 
other AMPs analyzed9.
Another important limitation of synthetic (and 
even natural) AMPs is their high manufacturing costs26, 
which would increase treatment costs, restricting its use to 
few special cases – or significantly hinder its use in poor 
countries, with very restricted resources. These high costs 
are related not only to the research process but also to the 
limited AMP expression and sometimes difficult synthesis 
process; thus, researches on new methods of production, 
with higher expression and cheaper processes, should be 
done to AMPs clinical use become a reality.
AMP administration
AMPs administration is a treatment’s feature that 
can both impair or improve the peptides potentials or 
limitations. It approaches both the peptide inoculation site 
and their association with devices that carry the molecules. 
Regarding peptide injection, Zhang et al.9 
interestingly compared the insertion of different AMPs 
in mice peritoneum and subcutaneous, finding that the 
mortality in the first case was higher than the second one, 
independently of the peptide used. This raises possibilities 
not only to further studies’ design but also to accurate others 
results’ interpretation.
The use of devices is another alternative to slightly 
modify the role of AMPs. Immobilization on a surface is 
a strategy that commonly reduces the peptide proteolytic 
degradation, co-precipitation and self-aggregation, while 
allows AMPs gradual release, minimizing the dose-
dependent toxicity, a frequent side effect8. However, this 
also impairs antimicrobial activity19, even though this 
does not necessarily invalidate the AMP. The lactoferrin 
derivative hLF1-11, for example, despite showing higher 
MIC when immobilized, could decrease adherent bacteria 
viability in device surface, being bacteriostatic, but not 
bactericidal8.
Analogous positive results were found by 
Banaschewski et al.31, who used a bovine lipid-extract 
surfactant (BLES) as AMP carrier. The antimicrobial 
activity of CRAMP, CATH-1, and LL-37 decreased, but 
only a slight diminution of CATH-2 activity was observed. 
Furthermore, the association of CATH-2 with BLES 
showed lower deleterious effects compared to CATH-2 
alone and maintained its safety in healthy mice lung – the 
mild pulmonary edema and inflammation caused when 
instilled by itself did not occur when it was used with BLES.
This field of AMP research becomes even more 
relevant once it enables improvement in catheters’ safe 
use. S. aureus is one of the most common causes of 
biomaterial-associated infections18 and AMPs insertion in 
these devices emerges as a possibility to control bacteria 
biofilm formation. In this context, a novel catheter assembly 
with titanium, silver, polyarginine, hyaluronic acid, and the 
AMP catestatin calls attention, as it shows, in vitro, lower 
inflammation response and higher human tolerance to 
implant - two majors problems associated with biomedical 
devices17.
CONCLUSION
S. aureus commonly belongs to humans’ microbiota, 
being associated with worse prognostic in intensive 
care units due to infections that sometimes could not be 
completely controlled by traditional treatments. Ergo, it 
is desirable that novel approaches are developed, and it 
is in this scenario that AMPs emerge as an alternative. 
Nonetheless, besides some positive results in infection 
control, the current data and knowledge about them seem 
to remain scarce and even controversial.
AMPs bactericidal and bacteriostatic activities were, 
in some cases, restricted to a single or few research groups, 
which not rarely achieve discrepant results in MIC and 
toxicity, according to strains or experimental conditions. 
The wide variety of peptides and the incomprehension 
about how their structure impact the antimicrobial action 
are also considerable obstacles to advance on their 
therapeutic potentials. Therefore, many AMPs keep in 
preclinical in vitro and in vivo studies or are even neglected 
before having its potentials carefully analyzed.
In this scope, further researches in AMPs are needed 
not only to discover new molecules, but also to enable 
their full characterization, as well as to ensure further 
progress - improving cheaper manufacturing process and 
study designs that are closer to the animal organism, for 
example, in aspects of salt concentration and membrane 
composition. These long-term projects will possibly 
support the prospective clinical use of AMPs in such a 
relevant context as infection.
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